TherapeuticsMD narrows Q3 net loss to $567K; license revenue rises to $547K

TherapeuticsMD, Inc.

2025-Q3 EPS reported -$0.21 revenue$1,094,000

Net loss from continuing operations of $567K ($0.05 per share) vs. $1.4M loss ($0.13) in Q3 2023.
License revenue from Mayne agreement totaled $547K, up from negative $53K in Q3 2023.
Total operating expenses fell 18.3% YoY to $1.4M on cost reductions after royalty transition.
Cash and equivalents stood at $5.0M as of Sept 30, 2024.
Company continues to evaluate strategic alternatives including M&A or asset sale; no timeline set.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.